Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies - Wikidata - awgldk - TriplyDB

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies

http://www.wikidata.org/entity/Q37169105

about

The broken "Off" switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance The emerging role of FTY720 (Fingolimod) in cancer treatment Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia Regulation of PP2A by Sphingolipid Metabolism and Signaling Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer.The Basic Biology of PP2A in Hematologic Cells and Malignancies Preclinical Metabolism, Pharmacokinetics and In Vivo Analysis of New Blood-Brain-Barrier Penetrant Fingolimod Analogues: FTY720-C2 and FTY720-Mitoxy FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model The differential effects of FTY720 on functional recovery and infarct size following myocardial ischaemia/reperfusion.Novel FTY720-Based Compounds Stimulate Neurotrophin Expression and Phosphatase Activity in Dopaminergic Cells.Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies Advances in the management of peritoneal mesothelioma Simultaneous and dose dependent melanoma cytotoxic and immune stimulatory activity of betulin A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia.Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.Role of phosphoinositide 3-kinase IA (PI3K-IA) activation in cardioprotection induced by ouabain preconditioning The phosphorylated form of FTY720 activates PP2A, represses inflammation and is devoid of S1P agonism in A549 lung epithelial cells.Protein phosphatase methylesterase-1 (PME-1) expression predicts a favorable clinical outcome in colorectal cancer.Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models.Novel B55α-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest.The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod.Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer.Fingolimod targeting protein phosphatase 2A differently affects IL-33 induced IL-2 and IFN-γ production in CD8(+) lymphocytes.Modulation of IL-33/ST2-TIR and TLR signalling pathway by fingolimod and analogues in immune cells.MYC-dependent recruitment of RUNX1 and GATA2 on the SET oncogene promoter enhances PP2A inactivation in acute myeloid leukemia.MPL W515L expression induces TGFβ secretion and leads to an increase in chemokinesis via phosphorylation of THOC5.Sphingosine 1-Phosphate Signaling and Its Pharmacological Modulation in Allogeneic Hematopoietic Stem Cell Transplantation.SET contributes to the epithelial-mesenchymal transition of pancreatic cancer.SETting OP449 into the PP2A-activating drug family.Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity.Phosphoproteomics Profiling of Nonsmall Cell Lung Cancer Cells Treated with a Novel Phosphatase Activator.Recent advances in phosphoproteomics and application to neurological diseases.PP2A deactivation is a common event in oral cancer and reactivation by FTY720 shows promising therapeutic potential.Macrocyclic peptides decrease c-Myc protein levels and reduce prostate cancer cell growth.FTY720 ameliorates renal fibrosis by simultaneously affecting leucocyte recruitment and TGF-β signalling in fibroblasts.Protein Phosphatase 2A in the Regulation of Wnt Signaling, Stem Cells, and Cancer.Clinicopathological effects of protein phosphatase 2, regulatory subunit A, alpha mutations in gastrointestinal stromal tumors.PPP2R1A regulated by PAX3/FOXO1 fusion contributes to the acquisition of aggressive behavior in PAX3/FOXO1-positive alveolar rhabdomyosarcoma.

P2860

Q26739246-C48D65B3-C28E-44D9-B8E8-18ABAE877E58 Q26748927-414124E4-36F5-43B0-9BD4-23EA2736CF9E Q26752430-B51C894E-1001-4336-A6ED-75DAC750A7B4 Q27026038-12F88F53-FF8F-4D8F-BD52-9F71D7782792 Q27308683-FF63B31D-47F6-4074-B000-B00846C4050A Q28088697-92D2377D-B04B-4026-8E59-6BC12086F6CE Q28553993-460542AB-116C-462E-9053-A43DC2F1B9C9 Q29248124-44595C06-D03A-4263-B2F8-8B46DDAE0C2D Q33613072-CC16EF5B-3A5E-4C41-974F-C82AE166DEE4 Q33889032-F33FA30A-3E28-448B-AC86-3AB0B252D3F5 Q33977247-531829DE-6FAC-482A-90AA-78567E08E4BB Q34043449-34817006-DC3C-4011-AC6D-64AA28A3E19D Q34137322-32541634-0A21-43F6-81B5-A93FA4DD20A3 Q35165322-2D15D713-AD9B-41D5-9EBD-0836A0751889 Q35953902-EE41BBB1-D568-407A-9BDD-8DE5E54F0A45 Q36020877-BBA23896-C587-4C76-B8B1-4336D8B89D3F Q36787700-5F5A2840-C590-416B-B221-800E6ED22806 Q37416615-26FE2192-C622-48B2-A9DC-5E73FCB460F3 Q37441510-BE695DEE-7FFD-4571-8C9C-7FB112B4EA09 Q37607196-D2D72EEC-090F-40F9-BFE7-8E2F9E74F637 Q37641562-767E13ED-4ACA-4640-ADA8-DB04DE3748E2 Q38546700-35816417-8E8A-4BC5-B86B-7E69E50AF516 Q38678579-2FC32603-3DD1-4848-BA21-F3DE6DF0530F Q38810636-11BA0664-849A-4D2E-B037-BE69B83F2236 Q38957804-DE8F902F-3F15-4362-A055-7ED8C5C4D3FF Q41553595-C96A3D08-6829-4D4D-A9CD-B998BA9B9652 Q41787058-79FA75FD-75D6-4614-AFC7-19E8F14F5058 Q41995676-D557126F-8BB9-44EC-B50B-4B464878F19F Q42100343-F8A24F6C-7069-49B2-99A9-593CADFDDD6F Q43094665-ADC0B1F8-E8E3-40E0-ACF0-1FABC9A5CC34 Q44320317-E6859386-18D9-46E2-AA23-DBFCED692593 Q47618603-01B55AAF-3F7D-49A4-A5AC-E8C0EF63AE23 Q47672478-06B3DB1F-4803-4595-A870-30EEAF8A153D Q48128686-A111D877-9566-4D24-AB1A-EFD6A701AF34 Q48151505-10D6C0FA-7D38-446A-8A04-449FFFFC2D19 Q48208586-BDC0C7CD-19BA-4D7A-A8EE-1F01F5E7FE93 Q50421347-7CA49E6A-56C9-4203-AEFB-8CF58B34EC06 Q51609445-CE5854DC-5D7F-4718-99EA-DF2BEB00A73E Q54977242-0E6C8342-46DE-451F-BFCE-F0B6EFBB5719

P2860

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies

http://www.wikidata.org/entity/Q37169105

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 07 August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Antagonistic activities of the ...... riven hematologic malignancies

@en

Antagonistic activities of the ...... iven hematologic malignancies.

@nl

type

label

Antagonistic activities of the ...... riven hematologic malignancies

@en

Antagonistic activities of the ...... iven hematologic malignancies.

@nl

prefLabel

Antagonistic activities of the ...... riven hematologic malignancies

@en

Antagonistic activities of the ...... iven hematologic malignancies.

@nl

P1433

Q37169105-F7B0ED0A-51C3-48F5-84FB-E6F27BF5EECF

P1476

Q37169105-E804E409-569A-4111-B631-87412D7E5507

P2093

Q37169105-01AC9D86-0EAE-485E-846D-78A4552E914B

Q37169105-01C1FC27-CEE5-49AC-8E8D-C00AD2376648

Q37169105-09233106-3A50-408B-9D6D-287200D598E5

Q37169105-0BD91629-ED0A-4CD0-84A7-01EF0E10D57C

Q37169105-18438CCC-EDB0-4FCE-AE66-E4CE27E6EB43

Q37169105-1A57BBAA-890B-4157-9DB8-FF6B69234EA6

Q37169105-1B0FD7C8-BE4D-4DEC-8C14-A563552976AD

Q37169105-26F3A42E-903D-4D7B-8D6C-346F605F5E27

Q37169105-2D510097-163B-4FE3-99DA-897CD3698C6A

Q37169105-3549C5A7-D61F-4944-90A1-B5274A2176AF

P2860

Q37169105-0528A6F7-72BF-41B7-B403-8168CB9950E1

Q37169105-076BEB8F-7CB7-4BD4-B98F-C7B536365820

Q37169105-0EEDBD61-9378-4F85-A97A-D034220F3D82

Q37169105-117F1724-4287-4121-968C-C25ABD1B5626

Q37169105-1E54B3FD-E563-4C05-850D-C4785E825710

Q37169105-231D95FB-4156-4CB0-94A9-E6589ADF3162

Q37169105-25B73A6A-3698-45EF-A118-D1D41CC82A71

Q37169105-26A45523-F23A-4F89-8B15-6231E3B04D98

Q37169105-2C2182F6-2B6A-4F50-B2FC-F27CF9592895

Q37169105-2C853F07-5BBC-42B6-8E28-59003B7EFBB0

P304

Q37169105-CD7E3BAD-B4AD-49F0-B4A0-D4F6F3451CD2

P31

Q37169105-19C4645D-AECE-44F6-9A3E-6460191CACFC

P356

Q37169105-5683D5C5-C559-4C1C-941E-BA2F4F433745

P407

Q37169105-5CBED60D-944D-4847-8F00-F76ACF21E66A

P433

Q37169105-2DF1908C-5D0B-4666-A386-F153DACEF855

P478

Q37169105-4DA34AFC-6815-40A3-BEDC-295B4B5F7C4B

P50

Q37169105-77F2775C-4F92-4297-9D3D-779281284CF3

Q37169105-97899F97-EEAD-470A-B332-DD17F021B333

Q37169105-B2C668D8-30DA-48CA-875C-AC3B94193E5D

P577

Q37169105-678EB234-E576-44C4-9A95-813750C8B79C

P5875

Q37169105-5005ACAD-7A28-4E52-AAF9-9AE8B991D7EA

P698

Q37169105-0EA0925D-E7D7-48D9-9C12-2BF207060C53

P932

Q37169105-400B2B2B-A66F-4647-947E-576575F8BCD2

P356

BLOOD-2013-03-492181

P1433

P1476

Antagonistic activities of the ...... riven hematologic malignancies

@en

P2093

Alistair Reid

http://www.w3.org/2001/XMLSchema#string

Ann-Kathrin Eisfeld

http://www.w3.org/2001/XMLSchema#string

Besim Ogretmen

http://www.w3.org/2001/XMLSchema#string

Christopher J Walker

http://www.w3.org/2001/XMLSchema#string

Danilo Perrotti

http://www.w3.org/2001/XMLSchema#string

Dragana Milojkovic

http://www.w3.org/2001/XMLSchema#string

Greg Ferenchak

http://www.w3.org/2001/XMLSchema#string

James R Van Brocklyn

http://www.w3.org/2001/XMLSchema#string

Jane Apperley

http://www.w3.org/2001/XMLSchema#string

Jason G Harb

http://www.w3.org/2001/XMLSchema#string

P2860

Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET

Involvement of protein phosphatase 2A in the interleukin-3-stimulated Jak2-Stat5 signaling pathway

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

Identification of in vivo phosphorylation sites of SET, a nuclear phosphoprotein encoded by the translocation breakpoint in acute undifferentiated leukemia

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

Differential biological activity of disease-associated JAK2 mutants

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

A gain-of-function mutation of JAK2 in myeloproliferative disorders

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

P304

1923-1934

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2013-03-492181

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P50

Ann-Kathrin Eisfeld

Alfonso Quintas-Cardama

P577

2013-08-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

255707396

http://www.w3.org/2001/XMLSchema#string

P698

23926298

http://www.w3.org/2001/XMLSchema#string

P932

3772499

http://www.w3.org/2001/XMLSchema#string